Enasidenib Mesylate vs Nivolumab

## Enasidenib Mesylate vs Nivolumab: Overview

This comparison examines the pharmacological differences between **Enasidenib Mesylate** and **Nivolumab**.

## Mechanism of Action

**Nivolumab**: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

## Pharmacokinetics

**Half-life**: Enasidenib Mesylate — N/A; Nivolumab — 27 days.

## Chemical Properties

**Type**: Enasidenib Mesylate — Small molecule; Nivolumab — Antibody.